^
    8d
    Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma (clinicaltrials.gov)
    P1, N=16, Completed, Beijing Boren Hospital | Recruiting --> Completed
    Trial completion
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • autologous CD7-CAR T cells
    over2years
    Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Beijing Boren Hospital | Trial primary completion date: Apr 2022 --> Apr 2023
    Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • autologous CD7-CAR T cells
    over2years
    Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma. (ASCO 2022)
    Autologous CD7 CAR T cell therapy was safe and effective in the induction of remission in r/r T-ALL/LBL patients, without signs of GVHD. Longer follow-up time of more cases will be used to further evaluate this therapy.
    CAR T-Cell Therapy • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    CD7 expression
    |
    autologous CD7-CAR T cells
    over3years
    Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Beijing Boren Hospital
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    autologous CD7-CAR T cells